The company's current and future development goals cover the following sectors-Anhui Union Pharmaceuticals Technology Co., Ltd., Intermediates

The company's current and future development goals cover the following sectors

Release time：

Sep 26,2022

The company integrates multiple resources and strives to build a large health industry and finance platform company integrating pharmaceutical, intelligent medical, biomedical research and development, industrial production and sales. The chemical reactions involved in the existing products include Friedel-Crafts reaction, nitration reaction, sulfonation reaction, hydrogenation reaction, fluorination reaction, chlorination reaction, bromination reaction, diazotization reaction, Grignard reaction and so on.

1) Pharmaceutical research and development;

2) Production of advanced intermediates and APIs in line with GMP quality system;

3) API quality research and preparation research and development;

4) Sales of pharmaceutical intermediates and APIs;

5) CDMO business;

6) Intelligent medical research and development

The chemical reactions involved in the existing products include Friedel-Crafts reaction, nitration reaction, sulfonation reaction, hydrogenation reaction, fluorination reaction, chlorination reaction, bromination reaction, diazotization reaction, Grignard reaction, etc.

The company plans to set up a synthetic biology research and development center and a microfabrication process development engineering research center.

Union Pharmaceutical has its own intermediate and API production plants managed according to the GMP system, and also undertakes CDMO business. It is hoped that cooperation with relevant partners will be carried out and strengthened in various fields to jointly contribute to the protection of human health.

Union Pharmaceutical has also been deeply involved in the field of small molecule nucleoside nucleic acid drugs for many years and has accumulated a certain amount of accumulation. With the development and application of artificial intelligence and big data, it is actively accelerating the deployment of high-end specialty APIs, preparing for the development of related preparations, and also for the development and application of artificial intelligence and big data. Follow-up innovative drug research and development to lay a solid foundation.

Related news